Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
- PMID: 14675663
- DOI: 10.1016/j.ygyno.2003.08.018
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
Abstract
Objective: The aim of this study was to identify clinical and pathologic characteristics of patients with uterine papillary serous carcinoma (UPSC) who were all surgically managed at a single institution. The identified characteristics were then correlated with overall survival (OS).
Methods: One hundred twenty-nine patients with FIGO stage I-IV UPSC who were surgically staged at the University of Texas M. D. Anderson Cancer Center between 1989 and 2002 were identified. For each patient, medical records and pathology reports were reviewed. The Kaplan-Meier method was used to generate OS data. Factors predictive of outcome were compared using the log-rank test and Cox regression analysis.
Results: There were 52 patients with stage I disease, 5 with stage II, 41 with stage III, and 31 with stage IV. The median age at the time of diagnosis was 68 years (range, 44-93 years). A personal history of breast cancer was reported by 12.4% of the patients, and a family history of breast cancer was reported by 16%. The 5-year OS among all patients was 45.9%. Among the stage I patients (IA, n = 19; IB, n = 26; and IC, n = 7), the 5-year OS was 62.9% (IA, 81.5%; IB, 58.6%; and IC, 34.3%). The 5-year OS for patients with stage III and IV disease was 37.3 and 19.9%, respectively. Pathologic features predictive of OS included lymph node status (P </= 0.01), lymph vascular invasion (P </= 0.05), and depth of uterine invasion (P </= 0.05). Among patients with no uterine invasion (n = 32), surgical staging revealed that 37% had stage III or IV disease. Among stage III patients, those who received chemotherapy had a longer OS than those who did not receive chemotherapy (P = 0.03).
Conclusion: In this population of nonselected patients with UPSC, approximately 20% had a personal or family history of breast cancer. Stage, lymph node status, lymph vascular invasion, and depth of myometrial invasion were all risk factors for a worse prognosis. Traditional risk factors, however, did not predict the presence or the absence of metastasis. Among patients with noninvasive uterine disease, there was a high proportion with abdominal metastasis. Therefore, complete surgical staging of these patients is vital in determining their prognosis.
Comment in
-
Uterine papillary serous carcinomas: the exigency for clinical trials.Gynecol Oncol. 2003 Dec;91(3):461-2. doi: 10.1016/j.ygyno.2003.10.031. Gynecol Oncol. 2003. PMID: 14675662 No abstract available.
Similar articles
-
Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):77-84. doi: 10.1016/s0360-3016(97)00581-6. Int J Radiat Oncol Biol Phys. 1998. PMID: 9422561
-
Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.Gynecol Oncol. 2001 May;81(2):279-86. doi: 10.1006/gyno.2001.6159. Gynecol Oncol. 2001. PMID: 11330963
-
Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients.Gynecol Oncol. 1998 Apr;69(1):69-73. doi: 10.1006/gyno.1998.4956. Gynecol Oncol. 1998. PMID: 9571001
-
Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.Tumori. 2016 Dec 1;102(6):593-599. doi: 10.5301/tj.5000531. Epub 2016 Aug 4. Tumori. 2016. PMID: 27514313 Review.
-
Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy.Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):767-78. doi: 10.1016/s0360-3016(00)00724-0. Int J Radiat Oncol Biol Phys. 2000. PMID: 11020574 Review.
Cited by
-
Robotic surgery compared with laparotomy for high-grade endometrial cancer.J Robot Surg. 2014 Jun;8(2):163-7. doi: 10.1007/s11701-013-0448-6. Epub 2014 Jan 12. J Robot Surg. 2014. PMID: 27637526
-
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer.Cancers (Basel). 2021 Nov 23;13(23):5877. doi: 10.3390/cancers13235877. Cancers (Basel). 2021. PMID: 34884986 Free PMC article.
-
Management of women with surgically staged 1 uterine papillary serous cancer.ISRN Obstet Gynecol. 2011;2011:146264. doi: 10.5402/2011/146264. Epub 2011 Sep 11. ISRN Obstet Gynecol. 2011. PMID: 21918723 Free PMC article.
-
Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.Int J Gynecol Pathol. 2015 Jan;34(1):57-64. doi: 10.1097/PGP.0000000000000109. Int J Gynecol Pathol. 2015. PMID: 25473754 Free PMC article.
-
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.Br J Cancer. 2009 Jan 13;100(1):89-95. doi: 10.1038/sj.bjc.6604814. Epub 2008 Dec 16. Br J Cancer. 2009. PMID: 19088718 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical